Ann: Publication comparing Cymerus MSCs to other MSCs, page-43

Off topic? Evidently moderated for speaking "fluent arse" as he calls it himself. Hilarious.

Exciting reading in this report that I was disappointed to see poo-pooed on MSB threads by a poster I normally respect for his objective and very well informed insights. People will be emotional. There is definite food for thought in this study for anyone interested in stem cells, irrespective of their personal investments in the space; emotional or financial.

Some pretty novel discoveries in this study, that should not be so readily dismissed:

"Importantly, our findings showed that the source of MSCs was responsible for more of the variability in the MSC secretome than the functional phenotype. This is of considerable interest considering the substantial differences between resting and licensed MSCs and underscores the critical importance of comprehending variability of MSC source, especially in the context of developing MSC therapies. Previously, it has not been possible to make this comparison as no prior studies have characterised the secretome of both MSC source and inflammatory phenotype in parallel. The separation of adult and natal tissue-derived MSC secretomes aligns with observations by Shin et al. who also reported that the secretome of natal tissue-derived MSCs (placenta derived and Wharton’s jelly derived-MSCs) is more diverse than that of adult tissue-derived MSCs (BM.MSCs and AT.MSCs)₄₅. Kehl et al. also specifically linked the complexity of CM from Wharton’s jelly-derived MSCs to a more complete angiogenic network and higher concentrations of angiogenesis-related proteins than were identified in either BM.MSC or AT.MSC derived CM₆₅. Corresponding with our findings, these suggest that some MSC lines may be more potent due simply to a greater proteomic output."